Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer

Changhua Zhang, Niranjan Awasthi, Margaret Schwarz, Roderich E. Schwarz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Peritoneal dissemination of gastric cancer is a common reason for unresectability, a frequent recurrence mechanism, and a common cause for death. The present study was performed to test peritoneal dissemination gastric cancer xenografts mouse models that would support survival outcome analyses. Materials and methods: Human gastric cancer cell lines AGS, NCI-N87, and SNU-16 were intraperitoneally injected into nude mice and severe combined immunodeficiency (SCID) mice. The peritoneal tumor formation and mouse survival were compared among different groups. Mice were treated with oxaliplatin (5 mg/kg) and NVP-BEZ235 (10 mg/kg). Results: The formation rate of peritoneal cancer after intraperitoneal injection of 5 × 106 SNU16, NCI-N87, and AGS cells was 2/8, 6/8, and 0/8 in nude mice, and 6/6, 6/6, and 0/6 in SCID mice, respectively. Median animal survival with peritoneal dissemination was 74 d for NCI-N87 cells (10 × 106), 95 d for SNU16 cells (10 × 106), 78 d for SNU16 cells (20 × 106), and 44 d for SNU16 cells (40 × 106). In a therapeutic experiment with 40 × 106 SNU16 cells, animal survival was significantly improved by oxaliplatin treatment compared with the control group (58.5 d versus 45 d, P <0.001), but not by NVP-BEZ235 (48 d versus 45 d, P = 0.249) treatment. In the accompanying subcutaneous SNU16 mouse model, relative tumor volume compared with controls was not significantly decreased by oxaliplatin treatment (P = 0.151) but by NVP-BEZ235 therapy (P = 0.008). Conclusions: Peritoneal gastric cancer xenografts were successfully established after intraperitoneal injection NCI-N87 and SNU16 cells. These findings provide a useful survival outcome assessment model for experimental gastric cancer research.

Original languageEnglish (US)
Pages (from-to)227-234
Number of pages8
JournalJournal of Surgical Research
Volume182
Issue number2
DOIs
StatePublished - Jun 15 2013
Externally publishedYes

Fingerprint

oxaliplatin
Heterografts
Stomach Neoplasms
Outcome Assessment (Health Care)
Survival
Severe Combined Immunodeficiency
Intraperitoneal Injections
Nude Mice
Therapeutics
Survival Analysis
Tumor Burden
Cause of Death
Neoplasms
Cell Survival
Theoretical Models
Recurrence
Cell Line
Control Groups
Research
dactolisib

Keywords

  • Gastric cancer
  • Mouse model
  • Peritoneal dissemination
  • Survival

ASJC Scopus subject areas

  • Surgery

Cite this

Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. / Zhang, Changhua; Awasthi, Niranjan; Schwarz, Margaret; Schwarz, Roderich E.

In: Journal of Surgical Research, Vol. 182, No. 2, 15.06.2013, p. 227-234.

Research output: Contribution to journalArticle

@article{058bbc73c35648d7897323d965fcee18,
title = "Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer",
abstract = "Background: Peritoneal dissemination of gastric cancer is a common reason for unresectability, a frequent recurrence mechanism, and a common cause for death. The present study was performed to test peritoneal dissemination gastric cancer xenografts mouse models that would support survival outcome analyses. Materials and methods: Human gastric cancer cell lines AGS, NCI-N87, and SNU-16 were intraperitoneally injected into nude mice and severe combined immunodeficiency (SCID) mice. The peritoneal tumor formation and mouse survival were compared among different groups. Mice were treated with oxaliplatin (5 mg/kg) and NVP-BEZ235 (10 mg/kg). Results: The formation rate of peritoneal cancer after intraperitoneal injection of 5 × 106 SNU16, NCI-N87, and AGS cells was 2/8, 6/8, and 0/8 in nude mice, and 6/6, 6/6, and 0/6 in SCID mice, respectively. Median animal survival with peritoneal dissemination was 74 d for NCI-N87 cells (10 × 106), 95 d for SNU16 cells (10 × 106), 78 d for SNU16 cells (20 × 106), and 44 d for SNU16 cells (40 × 106). In a therapeutic experiment with 40 × 106 SNU16 cells, animal survival was significantly improved by oxaliplatin treatment compared with the control group (58.5 d versus 45 d, P <0.001), but not by NVP-BEZ235 (48 d versus 45 d, P = 0.249) treatment. In the accompanying subcutaneous SNU16 mouse model, relative tumor volume compared with controls was not significantly decreased by oxaliplatin treatment (P = 0.151) but by NVP-BEZ235 therapy (P = 0.008). Conclusions: Peritoneal gastric cancer xenografts were successfully established after intraperitoneal injection NCI-N87 and SNU16 cells. These findings provide a useful survival outcome assessment model for experimental gastric cancer research.",
keywords = "Gastric cancer, Mouse model, Peritoneal dissemination, Survival",
author = "Changhua Zhang and Niranjan Awasthi and Margaret Schwarz and Schwarz, {Roderich E.}",
year = "2013",
month = "6",
day = "15",
doi = "10.1016/j.jss.2012.10.052",
language = "English (US)",
volume = "182",
pages = "227--234",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer

AU - Zhang, Changhua

AU - Awasthi, Niranjan

AU - Schwarz, Margaret

AU - Schwarz, Roderich E.

PY - 2013/6/15

Y1 - 2013/6/15

N2 - Background: Peritoneal dissemination of gastric cancer is a common reason for unresectability, a frequent recurrence mechanism, and a common cause for death. The present study was performed to test peritoneal dissemination gastric cancer xenografts mouse models that would support survival outcome analyses. Materials and methods: Human gastric cancer cell lines AGS, NCI-N87, and SNU-16 were intraperitoneally injected into nude mice and severe combined immunodeficiency (SCID) mice. The peritoneal tumor formation and mouse survival were compared among different groups. Mice were treated with oxaliplatin (5 mg/kg) and NVP-BEZ235 (10 mg/kg). Results: The formation rate of peritoneal cancer after intraperitoneal injection of 5 × 106 SNU16, NCI-N87, and AGS cells was 2/8, 6/8, and 0/8 in nude mice, and 6/6, 6/6, and 0/6 in SCID mice, respectively. Median animal survival with peritoneal dissemination was 74 d for NCI-N87 cells (10 × 106), 95 d for SNU16 cells (10 × 106), 78 d for SNU16 cells (20 × 106), and 44 d for SNU16 cells (40 × 106). In a therapeutic experiment with 40 × 106 SNU16 cells, animal survival was significantly improved by oxaliplatin treatment compared with the control group (58.5 d versus 45 d, P <0.001), but not by NVP-BEZ235 (48 d versus 45 d, P = 0.249) treatment. In the accompanying subcutaneous SNU16 mouse model, relative tumor volume compared with controls was not significantly decreased by oxaliplatin treatment (P = 0.151) but by NVP-BEZ235 therapy (P = 0.008). Conclusions: Peritoneal gastric cancer xenografts were successfully established after intraperitoneal injection NCI-N87 and SNU16 cells. These findings provide a useful survival outcome assessment model for experimental gastric cancer research.

AB - Background: Peritoneal dissemination of gastric cancer is a common reason for unresectability, a frequent recurrence mechanism, and a common cause for death. The present study was performed to test peritoneal dissemination gastric cancer xenografts mouse models that would support survival outcome analyses. Materials and methods: Human gastric cancer cell lines AGS, NCI-N87, and SNU-16 were intraperitoneally injected into nude mice and severe combined immunodeficiency (SCID) mice. The peritoneal tumor formation and mouse survival were compared among different groups. Mice were treated with oxaliplatin (5 mg/kg) and NVP-BEZ235 (10 mg/kg). Results: The formation rate of peritoneal cancer after intraperitoneal injection of 5 × 106 SNU16, NCI-N87, and AGS cells was 2/8, 6/8, and 0/8 in nude mice, and 6/6, 6/6, and 0/6 in SCID mice, respectively. Median animal survival with peritoneal dissemination was 74 d for NCI-N87 cells (10 × 106), 95 d for SNU16 cells (10 × 106), 78 d for SNU16 cells (20 × 106), and 44 d for SNU16 cells (40 × 106). In a therapeutic experiment with 40 × 106 SNU16 cells, animal survival was significantly improved by oxaliplatin treatment compared with the control group (58.5 d versus 45 d, P <0.001), but not by NVP-BEZ235 (48 d versus 45 d, P = 0.249) treatment. In the accompanying subcutaneous SNU16 mouse model, relative tumor volume compared with controls was not significantly decreased by oxaliplatin treatment (P = 0.151) but by NVP-BEZ235 therapy (P = 0.008). Conclusions: Peritoneal gastric cancer xenografts were successfully established after intraperitoneal injection NCI-N87 and SNU16 cells. These findings provide a useful survival outcome assessment model for experimental gastric cancer research.

KW - Gastric cancer

KW - Mouse model

KW - Peritoneal dissemination

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84877718320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877718320&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2012.10.052

DO - 10.1016/j.jss.2012.10.052

M3 - Article

VL - 182

SP - 227

EP - 234

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -